<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672191</url>
  </required_header>
  <id_info>
    <org_study_id>AGS-004-001</org_study_id>
    <nct_id>NCT00672191</nct_id>
  </id_info>
  <brief_title>Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV</brief_title>
  <official_title>A Phase II Study Testing the Activity and Safety of AGS-004 as an Immunotherapeutic in Successfully ART-Treated Subjects Infected With HIV-1 in Combination With ART Followed by ART Interruption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Argos Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Argos Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication&#xD;
      and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated,&#xD;
      to determine if immunotherapy increases the body's immune response to HIV-1; and, to&#xD;
      determine if after stopping anti-HIV drugs, immunotherapy can control the HIV-1 virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although chronic ART raises cluster of differentiation CD 4+ T cell counts and improves&#xD;
      immune function, the immune systems' ability to control HIV-1 replication is not improved.&#xD;
      AGS-004 is an immunotherapeutic agent made from autologous DCs co electroporated with&#xD;
      amplified in vitro transcribed (IVT) ribonucleic acid (RNA) encoding CD40L and with IVT RNA&#xD;
      encoding three or four autologous HIV-1 antigens. The HIV-1 RNA is derived from the plasma&#xD;
      sample taken immediately prior to the initiation of ART.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of AGS-004 therapy to improve immune control of HIV-1 replication</measure>
    <time_frame>Study Week 26 through end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma HIV-1 RNA set point</measure>
    <time_frame>Study Week 26 through end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell responses to AGS-004 therapy and exploratory studies to investigate the mechanism of action of AGS-004.</measure>
    <time_frame>Study Week 26 through end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AGS-004</measure>
    <time_frame>Study Week 26 through end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AGS-004</intervention_name>
    <description>HIV-1 Immune Therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 60 years of age&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Subjects must be on their first ART regimen for at least 3 months: 2 NRTIs together&#xD;
             with an NNRTI and/or at least 1 PI (prior changes to ART regimen are allowed if due to&#xD;
             tolerability, guideline change, or to simply dosing but not for viral control)&#xD;
&#xD;
          -  Durable viral suppression (below limit of detection) for at least 3 months prior ot&#xD;
             Screening&#xD;
&#xD;
          -  CD4+ T cell count ≥ 450 cells/mm3 for at least 90 days immediately prior to Screening&#xD;
&#xD;
          -  Availability of ≥ 1.2 mL of continually frozen plasma (may have been thawed and&#xD;
             refrozen only once) drawn no more than 90 days before starting ART and preferably&#xD;
             within 30 days.&#xD;
&#xD;
          -  Pre-ART plasma HIV-1 RNA levels of ≥ 15,000 copies/mL at the time the plasma was&#xD;
             archived before commencing ART&#xD;
&#xD;
          -  Pre-ART nadir CD4+ T cell count ≥ 200 cells/mm3 (cell count of &lt; 200 cells/mm3 on one&#xD;
             occasion is allowed if subsequent pre-ART CD4+ cell counts were &gt; 200 cells/mm3 on at&#xD;
             least two time points.&#xD;
&#xD;
          -  Laboratory values obtained at Screening and confirmed just prior to Baseline Day 1:&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x upper limit of normal (ULN);&#xD;
&#xD;
               -  AST (SGOT), ALT (SG'PT), and alkaline phosphatase ≤ 3 x ULN;&#xD;
&#xD;
               -  ANC ≥ 750 cells/mm3;&#xD;
&#xD;
               -  Hemoglobin ≥ 10 g/dL; and,&#xD;
&#xD;
               -  Platelet count ≥ 75,000/mm3&#xD;
&#xD;
          -  Female subjects of reproductive potential must have a negative serum or urine&#xD;
             pregnancy test with a sensitivity of at most 50 mIU/mL performed within 30 days prior&#xD;
             to Screening.&#xD;
&#xD;
          -  All subjects must agree not to participate in a conception process and use&#xD;
             contraception.&#xD;
&#xD;
          -  Ability to communicate effectively with study personnel; considered reliable, willing,&#xD;
             and cooperative in terms of compliance with the Protocol requirements.&#xD;
&#xD;
          -  Voluntary informed consent given to participate in the study.&#xD;
&#xD;
          -  Successful RNA amplification of at least 3 antigens (must include Gag).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-2 antibody positive.&#xD;
&#xD;
          -  Positive test for other infectious diseases including:&#xD;
&#xD;
               -  clinically active, untreated syphilis (positive rapid plasma regain test (RPR)&#xD;
&#xD;
               -  clinically active hepatitis B infection (positive Hep B surface antigen HBsAg)&#xD;
&#xD;
               -  active hepatitis C infection or any history of hepatitis C infection&#xD;
&#xD;
               -  positive test for HTLV Type I or Type II antibody&#xD;
&#xD;
          -  Any acute infection or serious medical illness within 14 days prior to study entry&#xD;
&#xD;
          -  History of lymph node irradiation or dissection&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Previous use of any HIV-1 immunotherapy, including IL-2&#xD;
&#xD;
          -  Use of hydroxyurea within 30 days prior to Screening&#xD;
&#xD;
          -  Immunodeficiency other than HIV-1 or requirements to take immuno-modulating&#xD;
             concomitant medications&#xD;
&#xD;
          -  Known allergy or sensitivity to the investigational immunotherapy or its formulation&#xD;
&#xD;
          -  Use of systemic corticosteroids and use of topical steroids over a total area&#xD;
             exceeding 15 cm2 within 4 weeks of Screening or anticipated need for periodic use of&#xD;
             corticosteroids during the study&#xD;
&#xD;
          -  Receipt of any immune modulators or suppressors within 30 days of Screening&#xD;
&#xD;
          -  Active autoimmune disease such as:&#xD;
&#xD;
               -  Rheumatoid arthritis&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Systemic lupus erythematosis&#xD;
&#xD;
               -  Ankylosing spondylitis&#xD;
&#xD;
               -  Hashimoto's disease&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Autoimmune hemolytic anemia&#xD;
&#xD;
               -  Immune thrombocytopenic purpura&#xD;
&#xD;
          -  Type I diabetes mellitus (insulin therapy for Type II diabetes is permitted)&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days of Screening or use of&#xD;
             investigational agents (previous use of expanded access ARTs is permitted)&#xD;
&#xD;
          -  Body weight less than 30 kg.&#xD;
&#xD;
          -  Changes in ART regimen due to virologic failure (not including toxicities)&#xD;
&#xD;
          -  Presence of factors predicting insufficient adherence to the protocol.&#xD;
&#xD;
          -  Any condition that in the assessment of the investigator would indicate that it is not&#xD;
             in the best interest of the subject or incompatible with the any aspect of the study&#xD;
             design, treatment plan, and study objectives for a subject to participate.&#xD;
&#xD;
          -  History or other evidence of severe illness, malignancy, or any other condition that&#xD;
             would make the subject, in the opinion of the investigator, unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Routy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona Loutfy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maple Leaf Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecile Tremblay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUM- Hotel Dieu de Montreal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Gill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Alberta Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Guy Baril, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinque Medical du Quartier Latin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvie Vezina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinque medicale l'Actuel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan B Angel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Walmsley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UHN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fiona Smaill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anita Rachlis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julio Montaner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health Care Society</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Jacobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Partnership Comprehensive Care Practice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Practice Comprehensive Care Practice Div of Onfectious Disease &amp; HIV Med</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Alberta Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2R0X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Care Society / The University of British Columbia / BC Centre for Excellence in HIV/AIDS</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L7R3X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maple Leaf Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique medicale l'Actuel</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medical du Quartier Latin</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <disposition_first_submitted>January 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 29, 2013</disposition_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Human immunodeficiency virus</keyword>
  <keyword>Immunodeficiency Virus, Human</keyword>
  <keyword>HIV-1</keyword>
  <keyword>ART</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>HAART</keyword>
  <keyword>highly active retroviral therapy</keyword>
  <keyword>cluster of differentiation CD 4+ T cell counts</keyword>
  <keyword>HIV-1 Subjects successfully ART treated</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

